Cargando…

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albshesh, Ahmad, Bannon, Lian, Sharar Fischler, Tali, Truyens, Marie, Vavricka, Stephan R., Tepes, Katja, Pugliese, Daniela, Savarino, Edoardo V., Zittan, Eran, Drobne, David, Roblin, Xavier, Bar-Gil Shitrit, Ariella, Armuzzi, Alessandro, Lobaton, Triana, Maharshak, Nitsan, Yanai, Henit, Ben-Horin, Shomron, Kopylov, Uri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095015/ https://www.ncbi.nlm.nih.gov/pubmed/37048587 http://dx.doi.org/10.3390/jcm12072503

Ejemplares similares

Acute Chest Pain as an Infusion Reaction to Vedolizumab
por: Levartovsky, Asaf, et al.
Publicado: (2022)

Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study
por: Kopylov, Uri, et al.
Publicado: (2023)

Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
por: Albshesh, Ahmad, et al.
Publicado: (2021)

Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
por: Levartovsky, Asaf, et al.
Publicado: (2023)

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study
por: Veisman, Ido, et al.
Publicado: (2021)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Adalimumab/ustekinumab/vedolizumab: COVID-19 infection: 7 case reports
Publicado: (2022)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

Prediction of Recurrent Emergency Department Visits among Patients with Crohn’s Disease: A Retrospective Study
por: Mahajna, Hussein, et al.
Publicado: (2020)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Deep Learning Multi-Domain Model Provides Accurate Detection and Grading of Mucosal Ulcers in Different Capsule Endoscopy Types
por: Kratter, Tom, et al.
Publicado: (2022)

Therapeutic drug monitoring in inflammatory bowel disease
por: Kopylov, Uri, et al.
Publicado: (2014)

Curcumin-QingDai Combination as Treatment for Moderate-Severe Ulcerative Colitis
por: Ben-Horin, Shomron, et al.
Publicado: (2022)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases
por: Rabinowitz, Keren Masha, et al.
Publicado: (2022)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)

Clinical outcomes of endoscopic balloon dilatation of intestinal strictures in patients with Crohn's disease
por: Winder, Ophir, et al.
Publicado: (2019)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
por: Vu, Michelle, et al.
Publicado: (2023)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
por: Mitrova, Katarina, et al.
Publicado: (2021)

Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases
por: Yanai, Henit, et al.
Publicado: (2022)

Role of integrin expression in the prediction of response to vedolizumab: A prospective real‐life multicentre cohort study
por: De Galan, Cara, et al.
Publicado: (2022)

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
por: Gisbert, Javier P., et al.
Publicado: (2023)

Magnetic resonance enterography or video capsule endoscopy – what do Crohn’s disease patients prefer?
por: Lahat, Adi, et al.
Publicado: (2016)

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
por: Ward, Mark G., et al.
Publicado: (2018)

Intestinal Tuberculosis and Crohn’s Disease is Always a Diagnostic Challenge: A Case Report and Review of the Literature on the Importance of Fecal Mycobacterial Cultures and the Limitations of Latent Infection Testing
por: Kurnick, Adam, et al.
Publicado: (2019)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
por: Pugliese, Daniela, et al.
Publicado: (2022)

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2022)

Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
por: Jeffrey, Angus W., et al.
Publicado: (2023)

Magnetic resonance enterography in pregnant women with Crohn’s disease: case series and literature review
por: Stern, Myriam D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vli33pni9m57uv437e51uisp9a